SCHEMBL3117441

SCHEMBL3117441

COc1ccc(Cn2ncc3c(-c4nc(C#N)c(N)o4)cccc32)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.48
HPGD P15428 10/20 0.48
MAPT P10636 10/20 0.48
KDM4E B2RXH2 10/20 0.48
GAA P10253 9/20 0.48
HSD17B10 Q99714 9/20 0.48
LMNA P02545 5/20 0.48
GLA P06280 2/20 0.48
CASP1 P29466 2/20 0.48
CASP7 P55210 2/20 0.48
ALOX15 P16050 2/20 0.48
NPSR1 Q6W5P4 3/20 0.42
MAPK1 P28482 4/20 0.39
PDE8B O95263 1/20 0.39
TP53 P04637 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
RAB9A P51151 2/20 0.39
KMT2A Q03164 2/20 0.39
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3112624 0.89 ALDH1A1 (0.48) ALDH1A1HPGDMAPTKDM4EGAA
SCHEMBL14023373 0.87 CNR1 (0.41) ALDH1A1HPGDMAPTKDM4EGAA
SCHEMBL13367133 0.82 CNR1 (0.40) ALDH1A1HPGDMAPTKDM4EGAA
SCHEMBL3124903 0.80 MAPT (0.53) ALDH1A1HPGDMAPTKDM4EGAA
SCHEMBL3125546 0.79 ALDH1A1 (0.48) ALDH1A1HPGDMAPTKDM4EGAA
SCHEMBL3289718 0.74 CNR1 (0.50) ALDH1A1HPGDMAPTHSD17B10LMNA
SCHEMBL12315708 0.73 CNR2 (0.49) ALDH1A1HPGDMAPTKDM4EHSD17B10
SCHEMBL14023375 0.73 ADORA2A (0.40) ALDH1A1HPGDMAPTKDM4EGAA
SCHEMBL21608367 0.69 NPBWR1 (0.47) ALDH1A1MAPTKDM4EGAALMNA
SCHEMBL14842958 0.69 CNR2 (0.62) ALDH1A1HPGDKDM4EGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170849-B1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LTD (GB) 2016-12-21 EP disclosed
EP-2170849-B1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LTD (GB) 2016-12-21 EP disclosed
US-9187465-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2015-11-17 US disclosed
US-9187465-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2015-11-17 US disclosed
US-9187465-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2015-11-17 US disclosed
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2015-02-26 US disclosed
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2015-02-26 US disclosed
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2015-02-26 US disclosed
US-8921544-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2014-12-30 US disclosed
US-8921544-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2014-12-30 US disclosed
US-8378095-B2 Oxazole tyrosine kinase inhibitors Saruem Limited (GB) 2013-02-19 US disclosed
US-8378095-B2 Oxazole tyrosine kinase inhibitors Saruem Limited (GB) 2013-02-19 US disclosed
US-8378095-B2 Oxazole tyrosine kinase inhibitors Saruem Limited (GB) 2013-02-19 US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 US disclosed
WO-2010055304-A2 PHARMACEUTICAL COMPOUNDS SAREUM LIMITED (GB) 2010-05-20 WO disclosed
WO-2010055304-A2 PHARMACEUTICAL COMPOUNDS SAREUM LIMITED (GB) 2010-05-20 WO disclosed
EP-2170849-A1 OXAZOLE TYROSINE KINASE INHIBITORS Sareum Limited (GB) 2010-04-07 EP disclosed
WO-2008139161-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 ALDH1A1 1403/4885HPGD 4701/4885MAPT 590/4885
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 ALDH1A1 1403/4885HPGD 4701/4885MAPT 590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.